Entering text into the input field will update the search result below

SIGA pushes ahead with smallpox treatment

Oct. 03, 2019 7:42 AM ETSIGA Technologies, Inc. (SIGA) StockSIGABy: Clark Schultz, SA News Editor
  • SIGA Technologies (NASDAQ:SIGA) says it reached concurrence with the FDA that no further clinical studies will be required for the IV formulation of TPOXX (tecovirimat) for the treatment of smallpox.
  • The company anticipates filing the new drug application for the formulation in 2020.
  • The FDA will not require additional efficacy data to support the NDA for the IV formulation.
  • Source: Press Release

Recommended For You

More Trending News

About SIGA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SIGA--
SIGA Technologies, Inc.